Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10065
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHu, Xiu Fengen
dc.contributor.authorXing, Pei Xiangen
dc.date.accessioned2015-05-15T23:24:04Z
dc.date.available2015-05-15T23:24:04Z
dc.date.issued2005-12-01en
dc.identifier.citationCurrent Opinion in Investigational Drugs (london, England : 2000); 6(12): 1266-71en
dc.identifier.govdoc16370393en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/10065en
dc.description.abstractMedarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonalen
dc.subject.otherAntigens, CD30.immunologyen
dc.subject.otherAntineoplastic Agents.pharmacology.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherDrug Screening Assays, Antitumoren
dc.subject.otherHodgkin Disease.drug therapy.immunologyen
dc.subject.otherHumansen
dc.subject.otherLymphoma, Large B-Cell, Diffuse.drug therapy.immunologyen
dc.titleMDX-060. Medarex.en
dc.typeJournal Articleen
dc.identifier.journaltitleCurrent opinion in investigational drugs (London, England : 2000)en
dc.identifier.affiliationThe Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australiaen
dc.description.pages1266-71en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/16370393en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.